Advisors Asset Management Inc. Sells 2,191 Shares of Halozyme Therapeutics, Inc. $HALO

Advisors Asset Management Inc. lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,553 shares of the biopharmaceutical company’s stock after selling 2,191 shares during the period. Advisors Asset Management Inc.’s holdings in Halozyme Therapeutics were worth $1,225,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. LPL Financial LLC lifted its stake in Halozyme Therapeutics by 17.1% during the first quarter. LPL Financial LLC now owns 242,432 shares of the biopharmaceutical company’s stock worth $15,470,000 after purchasing an additional 35,429 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in shares of Halozyme Therapeutics during the 1st quarter worth $264,000. Natixis Advisors LLC boosted its stake in Halozyme Therapeutics by 20.4% in the first quarter. Natixis Advisors LLC now owns 143,745 shares of the biopharmaceutical company’s stock valued at $9,172,000 after buying an additional 24,311 shares in the last quarter. LSV Asset Management grew its position in Halozyme Therapeutics by 41.9% in the first quarter. LSV Asset Management now owns 895,191 shares of the biopharmaceutical company’s stock valued at $57,122,000 after acquiring an additional 264,130 shares during the last quarter. Finally, Jupiter Asset Management Ltd. bought a new position in Halozyme Therapeutics in the first quarter valued at about $3,845,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on HALO shares. Weiss Ratings restated a “buy (b)” rating on shares of Halozyme Therapeutics in a research note on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Friday. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $75.10.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $68.48, for a total value of $136,960.00. Following the completion of the transaction, the director directly owned 42,952 shares of the company’s stock, valued at approximately $2,941,352.96. This trade represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Nicole Labrosse sold 2,227 shares of the business’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the transaction, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 110,227 shares of company stock worth $8,028,955. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Down 1.8%

Shares of HALO opened at $71.39 on Monday. The stock’s 50-day moving average price is $69.25 and its two-hundred day moving average price is $63.96. Halozyme Therapeutics, Inc. has a 12 month low of $46.26 and a 12 month high of $79.50. The company has a market capitalization of $8.39 billion, a PE ratio of 16.34, a PEG ratio of 0.35 and a beta of 1.18. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same period last year, the company earned $1.27 earnings per share. The firm’s revenue was up 22.1% compared to the same quarter last year. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.